| Autor: |
Sadasivam, Pragalath, Khanapur, Shivashankar, Hartimath, Siddesh V., Ramasamy, Boominathan, Cheng, Peter, Feng, Chin Zan, Green, David, Davis, Christopher, Goggi, Julian L., Robins, Edward G., Yan, Ran |
| Zdroj: |
Journal of Medicinal Chemistry; March 2024, Vol. 67 Issue: 6 p5064-5074, 11p |
| Abstrakt: |
Protein-based 18F-PET tracers offer new possibilities in early disease detection and personalized medicine. Their development relies heavily on the availability and effectiveness of 18F-prosthetic groups. We prepared and evaluated a novel arginine-selective prosthetic group, 4-[18F]fluorophenylglyoxal ([18F]FPG). [18F]FPG was radiosynthesized by a one-pot, two-step procedure with a non-decay-corrected (n.d.c.) isolated radiochemical yield (RCY) of 41 ± 8% (n= 10). [18F]FPG constitutes a generic tool for 18F-labeling of various proteins, including human serum albumin (HSA), ubiquitin, interleukin-2, and interleukin-4 in ∼30–60% n.d.c. isolated RCYs. [18F]FPG conjugation with arginine residues is highly selective, even in the presence of a large excess of lysine, cysteine, and histidine. [18F]FPG protein conjugates are able to preserve the binding affinity of the native proteins while also demonstrating excellent in vivostability. The [18F]FPG-HSA conjugate has prolonged blood retention, which can be applied as a potential blood pool PET imaging agent. Thus, [18F]FPG is an arginine-selective bioconjugation reagent that can be effectively used for the development of 18F-labeled protein radiopharmaceuticals. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
